Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Non-Current Liabilities (2016 - 2024)

Aptevo Therapeutics (APVO) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $10.8 million as the latest value for Q4 2024.

  • Quarterly Total Non-Current Liabilities fell 14.14% to $10.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Dec 2024, down 14.14% year-over-year, with the annual reading at $10.8 million for FY2024, 14.14% down from the prior year.
  • Total Non-Current Liabilities hit $10.8 million in Q4 2024 for Aptevo Therapeutics, up from $10.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $55.4 million in Q4 2021 to a low of $10.4 million in Q2 2024.
  • Historically, Total Non-Current Liabilities has averaged $22.2 million across 5 years, with a median of $12.6 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 49.88% in 2021 and later tumbled 70.68% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $37.0 million in 2020, then skyrocketed by 49.88% to $55.4 million in 2021, then tumbled by 70.68% to $16.2 million in 2022, then dropped by 22.29% to $12.6 million in 2023, then decreased by 14.14% to $10.8 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for APVO at $10.8 million in Q4 2024, $10.7 million in Q3 2024, and $10.4 million in Q2 2024.